null

null

null

null

null

null

null

null

null

Minimal debt; micro-cap medical device company (~$1-2M revenue) with near-zero long-term debt; 20% rate rise has negligible interest expense impact

Virtually no floating-rate debt exposure; primary sensitivity is equity financing cost and investor discount rates on future cash flows

Low intensity; China and India supply >60% of global API inputs, creating concentration risk.

1) Specialty optical glass/fiber from Asian manufacturers; 2) Precision medical-grade plastics potentially sourced via China-dependent polymer supply chains

Minimal international revenue; limited sovereign currency devaluation exposure; most sales are US-domestic hospital/surgical center transactions

Predominantly US-based revenue (~90%+); negligible exposure to EUR, GBP, or EM currency devaluation in current revenue mix

Low intensity; commodities: Active Pharmaceutical Ingredients, Rare Earth Elements, Natural Gas (energy), Plastics/Resins, Ethanol, Packaging Materials; geopolitical: China and India supply >60% of global API inputs, creating concentration risk.

High dependency on specialized optical fiber and trocar component suppliers; likely one or two sole-source vendors for proprietary lighted cannula components

Medical device hardware manufacturer; not cloud-dependent; termination of cloud account would affect administrative functions only, not core product delivery

Minimal SaaS or cloud-delivered service layer; business continuity risk from cloud termination is low; primary operations are physical device manufacturing and sales

No material API coupling risk; product is a physical surgical device; software integration limited to basic ERP/CRM tools easily substituted

Low Howey Test risk; revenue model is straightforward medical device product sales; no token, profit-sharing, or passive investment structure present

Very High

Minimal GDPR/CCPA exposure; company collects limited patient data; primary data is B2B sales and distributor contacts, low regulatory compliance burden

Low antitrust risk; niche surgical visualization device market with small market share; no dominant position warranting regulatory scrutiny

Very High burden; regimes: FDA, CMS, HHS, HIPAA, EMA, OIG; Drug pricing legislation and approval delays directly compress revenue visibility.

Nearly 100% transactional; device and disposable sales with no recurring subscription model; occasional repeat purchase from hospitals constitutes informal retention

Hardware device sales plus single-use disposable components (razor-and-blade model potential but underdeveloped); primary vector is capital equipment sale

Premium niche pricing for specialized lighted cannulas; limited pricing power stress-tested against GPO contracts and hospital budget cuts; ASP pressure likely

Moderate-low; faces hospital GPO pricing pressure and potential competition from larger device makers; differentiation via proprietary optical design provides some buffer

83.8% Gross Margin (Premium (>60%))

No free-rider problem; physical disposable device requires repurchase; churn risk is surgeons switching to competitor products or reverting to conventional techniques

Revenue growth is largely headcount-linear; scaling requires additional sales reps, manufacturing staff; limited operational leverage at current micro-cap scale

High marginal cost of growth; each incremental revenue dollar requires sales force expansion and manufacturing capacity; gross margins ~50-60% but SG&A-heavy

Not applicable; no franchise network; direct and distributor sales model only

At 10x scale, CAC would require significant sales force investment; surgical adoption driven by KOL physicians; unit economics challenged without GPO penetration

No meaningful network effects; device utility is standalone; adoption depends on individual surgeon preference and hospital procurement, not user-base size

-8.5% Return on Assets (Negative equity)

Moderate resilience; elective surgery volumes decline in recessions but neurosurgery and spine procedures are semi-elective with relatively stable demand

Neurosurgeons and spine surgeons at US hospitals and ASCs; high concentration risk if top 20 surgeon customers represent majority of revenue

Hospital procurement/GPO administrators and distributors; secondary segment with purchasing leverage that can compress margins and create dependency

["11-0000 Management Occupations", "13-0000 Business and Financial Operations Occupations", "15-0000 Computer and Mathematical Occupations", "19-0000 Life, Physical, and Social Science Occupations", "21-0000 Community and Social Service Occupations", "23-0000 Legal Occupations", "29-0000 Healthcare Practitioners and Technical Occupations", "31-0000 Healthcare Support Occupations", "41-0000 Sales and Related Occupations", "43-0000 Office and Administrative Support Occupations", "51-0000 Production Occupations"]

0.32 (HIL — ~32% of characteristic roles agent-automatable)

0.3% CapEx / Revenue (Low-CapEx Asset-Light)

0001424768

VYCO